Peter Venner

14.7k total citations · 3 hit papers
116 papers, 8.4k citations indexed

About

Peter Venner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Peter Venner has authored 116 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Pulmonary and Respiratory Medicine, 44 papers in Oncology and 30 papers in Surgery. Recurrent topics in Peter Venner's work include Prostate Cancer Treatment and Research (45 papers), Prostate Cancer Diagnosis and Treatment (22 papers) and Renal cell carcinoma treatment (20 papers). Peter Venner is often cited by papers focused on Prostate Cancer Treatment and Research (45 papers), Prostate Cancer Diagnosis and Treatment (22 papers) and Renal cell carcinoma treatment (20 papers). Peter Venner collaborates with scholars based in Canada, United States and India. Peter Venner's co-authors include Malcolm J. Moore, Scott North, D. Scott Ernst, I. F. Tannock, David Osoba, Joseph D. Ruether, C Coppin, A. J. Neville, Kim N. and Kerry S. Courneya and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Peter Venner

115 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

2009 1.5k citations Bernhard J. Eigl, Scott North et al. Journal of Clinical Oncology profile →
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1996 1.2k citations I. F. Tannock, David Osoba et al. Journal of Clinical Oncology profile →
Resistance Exercise in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

2003 614 citations Peter Venner et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Venner Canada	40	4.8k	3.3k	1.9k	1.8k	1.5k	116	8.4k
Christopher L. Amling United States	54	7.6k 1.6×	2.3k 0.7×	1.2k 0.6×	2.1k 1.2×	1.5k 1.0×	289	10.3k
Anil Kapoor Canada	44	5.3k 1.1×	2.1k 0.6×	4.7k 2.4×	2.1k 1.2×	2.3k 1.5×	403	9.9k
Armen Aprikian Canada	48	4.2k 0.9×	2.0k 0.6×	2.2k 1.1×	3.0k 1.7×	1.4k 0.9×	279	8.7k
Scott North Canada	39	5.5k 1.1×	2.8k 0.8×	2.6k 1.3×	1.2k 0.7×	2.2k 1.5×	193	7.6k
Sergio Serni Italy	40	3.1k 0.6×	1.5k 0.5×	2.0k 1.1×	1.4k 0.8×	974 0.6×	247	7.0k
Umberto Capitanio Italy	53	9.7k 2.0×	1.9k 0.6×	4.3k 2.2×	4.2k 2.4×	1.6k 1.1×	416	12.7k
David G. McLeod United States	61	9.7k 2.0×	2.5k 0.8×	3.0k 1.6×	1.9k 1.1×	2.4k 1.6×	271	13.3k
Richard E. Greenberg United States	44	4.6k 0.9×	1.1k 0.3×	3.0k 1.6×	2.2k 1.2×	1.2k 0.8×	200	7.1k
James M. McKiernan United States	52	5.1k 1.1×	2.1k 0.6×	4.3k 2.3×	4.7k 2.6×	1.6k 1.1×	340	10.6k
R. Jeffrey Karnes United States	59	8.5k 1.8×	2.0k 0.6×	2.3k 1.2×	2.8k 1.6×	2.4k 1.6×	428	12.4k

Countries citing papers authored by Peter Venner

Since Specialization

Citations

This map shows the geographic impact of Peter Venner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Venner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Venner more than expected).

Fields of papers citing papers by Peter Venner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Venner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Venner. The network helps show where Peter Venner may publish in the future.

Co-authorship network of co-authors of Peter Venner

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Venner. A scholar is included among the top collaborators of Peter Venner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Venner. Peter Venner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kolinsky, Michael, Bryan Donnelly, Adrian Fairey, et al.. (2020). Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada. BMJ Open. 10(10). e037222–e037222. 9 indexed citations

Bjarnason, Georg A., Jennifer J. Knox, Christian Kollmannsberger, et al.. (2019). The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. European Journal of Cancer. 108. 69–77. 24 indexed citations

Lalani, Aly‐Khan A., D.Y.C. Heng, Lori Wood, et al.. (2016). Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience. Annals of Oncology. 27. vi285–vi285. 3 indexed citations

Huang, Fleur, Brita Danielson, Peter Venner, et al.. (2016). Avascular Necrosis of the Femoral Head After Palliative Radiotherapy in Metastatic Prostate Cancer: Absence of a Dose Threshold?. Cureus. 8(3). e521–e521. 7 indexed citations

Eigl, Bernhard J., Peter Venner, Sébastien J. Hotte, et al.. (2011). A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Annals of Oncology. 23(1). 53–58. 29 indexed citations

Elhilali, M., M.E. Gleave, Yves Fradet, et al.. (2000). Placebo‐associated remissions in a multicentre, randomized, double‐blind trial of interferon γ‐1b for the treatment of metastatic renal cell carcinoma. British Journal of Urology. 86(6). 613–618. 39 indexed citations

McLeod, David G., Paul F. Schellhammer, Nicholas J. Vogelzang, et al.. (1999). Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Prostate. 40(4). 218–224. 19 indexed citations

Shipley, William U., Kathryn Winter, Donald S. Kaufman, et al.. (1998). Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.. Journal of Clinical Oncology. 16(11). 3576–3583. 364 indexed citations

Sarosdy, Michael F., Paul F. Schellhammer, Roohollah Sharifi, et al.. (1998). Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology. 52(1). 82–88. 36 indexed citations

10.

Schellhammer, Paul F., Roohollah Sharifi, Norman L. Block, et al.. (1997). Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial. Urology. 50(3). 330–336. 123 indexed citations

11.

Tester, William, Richard Caplan, John Heaney, et al.. (1996). Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.. Journal of Clinical Oncology. 14(1). 119–126. 201 indexed citations

12.

Tannock, I. F., David Osoba, Martin R. Stockler, et al.. (1996). Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.. Journal of Clinical Oncology. 14(6). 1756–1764. 1202 indexed citations breakdown →

13.

Schellhammer, Paul F., Roohollah Sharifi, Norman L. Block, et al.. (1996). A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone–Releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression. Cancer. 78(10). 2164–2169. 31 indexed citations

14.

Moore, Malcolm J., David Osoba, Keefe Murphy, et al.. (1994). Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.. Journal of Clinical Oncology. 12(4). 689–694. 132 indexed citations

15.

Warr, David, Peter Venner, Joseph L. Pater, et al.. (1993). A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. European Journal of Cancer. 29(1). 33–36. 29 indexed citations

16.

Eisenhauer, Elizabeth A., Malcolm J. Moore, Peter Venner, et al.. (1993). Gemcitabine in advanced renal cell carcinoma. Annals of Oncology. 4(4). 331–332. 45 indexed citations

17.

Tester, William, Arthur T. Porter, Sucha O. Asbell, et al.. (1993). Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of rtog protocol 85-12. International Journal of Radiation Oncology*Biology*Physics. 25(5). 783–790. 200 indexed citations

18.

Skillings, Jamey, Rafal Wierzbicki, Elizabeth A. Eisenhauer, et al.. (1992). A Phase II Study of Recombinant Tumor Necrosis Factor in Renal Cell Carcinoma. Journal of Immunotherapy. 11(1). 67–70. 30 indexed citations

19.

Dundas, G., Arthur T. Porter, & Peter Venner. (1990). Prostate-specific antigen: Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker. Cancer. 66(1). 45–48. 23 indexed citations

20.

Elhilali, M., Yves Fradet, Bruno Laroche, et al.. (1988). Total Androgen Blockade for Metastatic Cancer of the Prostate. American Journal of Clinical Oncology. 11. S187–190. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact